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Abstract
OBJECTIVE: To investigate the mechanism underly-
ing the anticancer effect of Artemisia species
through the inhibition of cell growth and induction
of apoptosis in breast carcinoma cells.
METHODS: To evaluate the anticancer activity of
methanol extracts of eight Artemisia species (Arte-
misia stolonifera, Artemisia selengensis, Artemisia
japonica, Artemisia Montana, Artemisia capillaris,
Artemisia sylvatica, Artemisia keiskeana, and Arte-
misia scoparia), we first investigated the prolifera-
tion of estrogen receptor (ER)-positive MCF-7
breast carcinoma cells exposed to 5 or 200 g/mL for
72 h. Apoptosis induction was assessed by an An-
nexin V binding assay in cells exposed to extracts at
a high concentration (200 g/mL). To verify the
mechanism of apoptosis, ER expression and its re-
lated signaling was investigated using an immu-
noblot assay under the same conditions.
RESULTS: MCF-7 cells showed the strongest antip-
roliferative response to the tested extracts. Howev-
er, a biphasic effect was observed: the extracts in-
hibited proliferation at high concentrations where-
as they stimulated it at low ones. ER expression was
similarly modulated by the extracts. However, all of
the extracts induced apoptosis at a high concentra-
tion (200 g/mL). Compared to the control level, ex-
posure to the extracts resulted in a remarkable in-
crease in the shift of cell populations.
CONCLUSION: The present study suggests that the
tested Artemisia species exerted their anticancer ef-
fects through the induction of apoptosis via an
ER-related pathway.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
A great deal of research has been conducted on the use
of plants for health-promoting purposes because most
people have broad experience with the use of
traditional plant-derived products (drug and
supplements). Among the numerous herbs used in
herbal medicine, growing interest has focused on the
use of Artemisia spp. for preventing and reducing the
risk of various cancers.1,2
We previously showed that Artemisia spp. had
significant anticancer, anti-inflammatory, and
antiobesity effects in vitro.3 The anticancer activity of
Artemisia spp., which involves the inhibition of
cellular proliferation, suggested the value of using
members of this genus in the production of bioactive
food supplements.
Moreover, according to published reports, various
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Artemisia spp. have been shown to have activity against
several cancer cell types, including hepatoma, gastric
cancer, leukemia, and skin cancer cells.4-7 The results of
these studies suggest that the anticancer activity of
Artemisia spp. depends on the type of cancer.
Breast cancer is one of the most frequently diagnosed
cancers in women, and a few studies have reported that
Artemisia preinceps,7 Artemisia asiatica,8 Artemisia
monosperma9 and Artemisia argyi10 have anticancer
effects on breast cancer. And some studies have shown
that Artemisia preinceps,8 Artemisia asiatica,9 Artemisia
monosperma,10 and Artemisia argyi11 have activities
against breast cancer.
According to a report based on the WHO database, an
increasing trend in breast cancer mortality was
observed in Japan and the Republic of Korea, while
breast cancer mortality (1990-2006) in the United
States and Europe (UK, Spain, and Germany) showed
a decreasing trend. However, the incidence of breast
cancer in these populations remains high. Released by
US National Cancer Institute, a report estimates that
one in eight women in the United States
(approximately 13.3% ) will develop breast cancer
during her lifetime.12,13 Breast cancer represents a group
of heterogeneous diseases with several clinical,
molecular, and histopathological forms, which makes
achieving effective chemotherapy problematic.
Estrogen receptor a (ERa), which is expressed in
approximately 70% of breast cancers,14 makes it
difficult to obtain a response to cancer drug treatment.
A need exists to study the targeting of ERa to develop
breast cancer therapies. The aim of the present study
was to evaluate the anticancer activity of eight
Artemisia species against human breast cancer MCF-7
cells and to investigate the underlying mechanism. We
found that the Artemisia spp. inhibited cellular
proliferation and induced apoptosis via ERa-related
pathway.
MATERIALS ANDMETHODS
Cells culture
The MCF-7 cells were used in the present study. These
cells were purchased from Korean Cell Line Bank,
Seoul, Republic of Korea. Each cells was routinely
maintained in either RPMI 1640 [Roswell Park
Memorial Institute medium, Invitrogen (Molecular
Probes), Gibco, Carlsbad, CA, USA] or DMEM
[Dulbeco's Modified Eagle's Medium, Invitrogen
(Molecular Probes), Gibco, Carlsbad, CA, USA],
supplemented with 10% Fetal bovine serum and
antibiotics (50 U/mL of penicillin and 50 μg/mL
streptomycin, Sigma-Aldrich Co., LLC., CA, USA) at
37℃ in a humidified atmosphere containing 5% CO2.
Each cell lines were plated at density of 5-1.0´104 cells/
well and 3-5´105 cells/well on 96-well and 6-well plates
for MTT assay and immunoblotting assay, respectively.
Preparation of eight kinds of extract
Abbreviation and voucher specimen number of
Artemisia species, which used in present study, was as
in the following; Artemisia stolonifera (AST,
PB4916.1), Artemisia selengensis (ASE, PB4913.1),
Artemisia japonica (AJA, PB4895.1), Artemisia
Montana (AMO, PB4920.1), Artemisia capillaris
(ACA, PB4894.2), Artemisia sylvatica (ASY,
PB4919.1), Artemisia keiskeana (AKE, PB4901.1),
and Artemisia scoparia (ASC, PB4893.5). Methanol
extracts of Artemisia species were supplied by
Herbarium of the KRIBB (The Korea Research
Institute of Bioscience & Biotechnology, Daejeon,
Korea). Taxonomical identification was confirmed by a
botanist and voucher specimens stored at the KRIBB
Herbarium. These extracts were diluted in DMSO
(dimethyl sulfoxide) to 25 mg/mL just before use.
MTT assay
Cell proliferation was determined using the MTT
assay. Each cell type was exposed to each extracts at a
concentration of 5-200 μg/mL for 24, 48, and 72 h.
After incubations, plated cells were incubated with
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT, Sigma Chemical Company, Perth,
Australia, 0.5mg/mL final concentration) for 4 h at 37℃ .
After discarding all medium from the plates, 100 μL of
DMSO was added to the each well. The plates were
placed for 5 min at room temperature with shaking, so
that complete dissolution of formazan was achieved.
The absorbance of the MTT formazan was determined
at 540 nm by a UV spectrophotometric plate reader
(Molecular Devices, LLC., CA, USA). From the plot
estimated was the value of IC50 (i.e., the concentration
of the extract required to inhibit cancer cell growth by
50% of the control level, that is, each cell was treated
with only compound solvent).
Apoptosis detection assay
Annexin V-FITC apoptosis kit (BD ApoAlert ™, BD
Biosciences Clontech, CA, USA) was used for
apoptosis detection. Cells were trypsinized, washed
twice in ice-cold PBS, and resuspended in 500 μL
binding buffer (Sigma-Aldrich Co., LLC., CA., USA).
Annexin V and propidium iodide solution were added
to the cell preparations and incubated for 25 min in
the dark. Binding buffer (400 μL) was then added to
each tube and the samples were analyzed by a FACS
Calibur instrument (BD Biosciences Clontech, CA,
USA) equipped with CellQuest 3.3 software (BD
Biosciences, CA, USA).
Immunoblotting assay
Each cell type was exposed to each extract for 72 h at
two concentrations (10 or 200 mg/mL). Then after,
cells were lysed in radioimmunoprecipitation assay
buffer (RIPA buffer; 1% nonidet P-40, 150 mM
NaCl, 0.05% deoxycholic acid, 1% sodium dodecyl
sulfate, 50 mM Tris, pH 7.5) containing protease
659
JTCM |www. journaltcm. com
Choi EJ et al. / Experimental Study
October 15, 2013 |Volume 33 | Issue 5 |
inhibitor for 1 h at 4℃. The supernatant was separated
by centrifugation, and protein concentration was
determined by Bradford protein assay kit II (Bio-rad
Laboratories, CA, USA). Proteins (25 μg/well)
denatured with sample buffer were separated by
10%-12% SDS-polyacrylamide gel. Proteins were
transferred onto nitrocellulose membranes (0.45 μm).
The membranes were blocked with a 1% BSA (bovine
serum albumin) solution for 3 h and washed twice
with PBS containing 0.2% Tween-20, and incubated
with the primary antibody overnight at 4℃.
Antibodies against estrogen receptor-a (ERa), cyclin
D1, Bcl-2, Bax and b-actin were purchased from Santa
Cruz (Santa Cruz Biotechnology, Inc., CA., USA) and
used to probe the separate membranes. The next day,
the immunoreaction was continued with the secondary
goat anti-rabbit horseradish-peroxidase-conjugated
antibody after washing for 2 h at room temperature.
The specific protein bands were detected by Opti-4CN
Substrate kit (Bio-rad Laboratories, CA, USA).
Statistical analyses
All data were expressed as percent compared with
vehicle-treated control cells, which were arbitrarily
assigned 100%. Data were analyzed by one-way analysis
of variance followed by Dunnett's multiple comparison
test (SigmaStat 3.1 statistical program, Systat Software
Inc., CA, USA). For all comparisons, differences were
considered statistically significant at P<0.05.
RESULTS
Antiproliferative effects of Artemisia extracts
We first examined the possible antiproliferatative
effects of different Artemisia extracts (AST, ASE, AJA,
AMO, ACA, ASY, AKE, and ASC) on ERa-positive
MCF-7 cell lines. When cell lines were exposed to
various concentrations of extracts (5-200 mg/mL) for
72 h (Figure 1), the antiproliferative effects of the
extracts were stronger in MCF-7 cells. However,
exposure to all extracts apart from the AST and ASE
extracts at concentrations less than 10 mg/mL
stimulated the proliferation of MCF-7 cells. Cell
growth was increased by 12% and 17% in MCF-7 cells
treated with ASE and AJA, respectively, compared to
controls, although the differences were not statistically
significant. Increases in the others were 5%-10% .
When applied at concentrations above 10 mg/mL, all
extracts significantly inhibited proliferation in a
dose-dependent manner (P<0.05). The response was
not greatly affected by exposure time (within a
12%-25% decrease in cells exposed to longer
treatment, compared to those exposed to the extracts
for 24 h). Notably, treatment with the ASE, AKE, and
ASC extracts at a concentration of 200 mg/mL for 72 h
reduced cell proliferation by 59.1%, 57.3%, and 64.7%,
respectively, compared to controls. The AST and ASE
extracts, when applied at higher concentrations
(200 mg/mL for 72 h), inhibited proliferation by
27.5% and 36.7%, respectively, compared to controls.
The other extracts showed approximately 15%-20%
inhibition.
Apoptosis induction by Artemisia extracts
To investigate Artemisia-induced apoptosis in MCF-7
cells, cells were treated with 200 mg/mL Artemisia
extract for 72 h (Figure 2). Compared with the control,
the number of apoptotic cells was increased significantly
by all of the tested extracts. As a similar pattern of
antiproliferative activity, treatment with ASE, AKE, and
ASC extracts increased the number of apoptotic cells by
53.9% , 61.3% , and 55.4% , respectively, compared to
the controls.
Effects of Artemisia extracts on ERa, cyclin D1 and
Bcl-2 expression and apoptosis induction
ERa expression was observed in MCF-7 cells exposed
to extracts (10 or 200 mg/mL) for 72 h (Figure 3).
ERa expression by MCF-7 cells exposed to extracts
showed a pattern similar to their antiproliferative
effects; that is, stimulation by lower some extracts
(ASE, AJA, AMO and ACA) concentrations was
detected. However, all extracts at higher concentrations
(200 mg/mL) reduced ERa expression. Moreover, all
extracts induced apoptosis in MCF-7 cells exposed to
200 mg/mL concentration through downregulation of
cyclin D1 and Bcl-2 expression.
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Figure 1 Effect of Artemisia extracts on cell proliferation in
estrogen receptor-a positive human breast MCF-7 cells
AST: Artemisia stolonifera; ASE: Artemisia selengensis; AJA:
Artemisia japonica; AMO: Artemisia montana; ACA: Artemis-
ia capillaris; ASY: Artemisia sylvatica; AKE: Artemisia
keiskeana; ASC: Artemisia scoparia. Cells were exposed to
each extracts at a concentration of 5-200 μg/mL for 72 h. All
data are reported as the percentage change in comparison
with the vehicle-only group.
DISCUSSION
Natural phytochemicals have been accepted as a type
of medicine, and epidemiological and experimental
studies have demonstrated that traditional herbs can
reduce the incidence of certain forms of cancer.15-18
Based on a study showing that Artemisia spp. have
beneficial biological activities, including anticancer,
antiobesity, and anti-inflammatory activities, we
investigated the anticancer mechanism of Artemisia
spp. in the present study.
The antiproliferative effects of Artemisia extracts on
ERa-positive T47D cells at high concentrations (>
100 mg/mL) for 72 h were significantly greater than
those of the extracts on ERa-negative HS578T cells,
although the extracts stimulated T47D cell growth at
lower concentrations and shorter times.3 This result is
consistent with those of the present study in that a
biphasic effect was observed, with the extracts
inhibiting proliferation at high concentrations and
stimulating it at low ones. When we investigated the
anticancer activity of methanol extracts of eight
Artemisia spp. (AST, ASE, AJA, AMO, ACA, ASY,
AKE and ASC) against ERa-positive MCF breast
carcinoma cells at a concentration of 10 or 200 mg/mL
for 72 h, MCF-7 cells showed the strongest
antiproliferative response to the tested extracts at high
concentrations but also exhibited growth at low
concentrations.
These data suggest that the antiproliferative activity of
Artemisia extracts involves an ERa-related pathway.
ERa is a member of the steroid receptor superfamily
that regulates processes such as growth and
differentiation in various target cells by regulating
transcription.19 ERa also plays an important role in the
development and progression of breast cancer.20 The
results of several recent epidemiological studies suggest
that phytoestrogens, plant-derived phenolic
compounds that structurally mimic the hormone
17β-estradiol,21 may reduce the risk of cancer. A new
strategy for breast cancer chemotherapy has been
targeted on ERa regulators among phytoestrogens. On
the other hand, previous studies suggest that
estrogen-like bioactive molecules may stimulate breast
cancer cell growth.22-24 Also, some drugs (e.g.,
tamoxifen, a representative selective estrogen receptor
modulator) act as ER agonists, and this ER-agonistic
activity may be associated with an increased risk of
endometrial cancer.25
Although it was not a significant effect, the Artemisia
extracts induced MCF-7 cell growth at low
concentrations (<10 mg/mL). This may be explained
by the fact that the genus Artemisia is comprised of
polyphenol-rich plants.26,27 Depending on their
polyphenol bioactive molecule content, Artemisia
extracts seem to have weak ER-agonist activity. This is
consistent with our data showing that the extracts
significantly reduced ERa expression at higher
concentration (200 mg/mL), but that some (ASE, AJA,
AMO, and ACA) induced it at a lower concentration
(10 mg/mL). The observed antiproliferative activities of
Artemisia are encouraging, but its use should be
carefully monitored. The Artemisia extracts reduced
cyclin D1 expression when applied to cells at a high
concentration. Cyclin D1 is a well-known target of
estrogens in breast cancer cells, and its induction is
important for the progression of cells through the G1
phase of the cell cycle.28 The results of several studies
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Figure 3 Effect of Artemisia extracts on estrogen receptor-a
(ERa, 66kDa), cyclin D1 (38 kDa), and Bcl-2 (26 kDa)
expression in ER-a positive human breast MCF-7 cells
A: control; B: AST (Artemisia stolonifera); C: ASE (Artemisia
selengensis); D: AJA (Artemisia japonica); E: AMO (Artemisia
Montana); F: ACA (Artemisia capillaris); G: ASY (Artemisia
sylvatica); H: AKE (Artemisia keiskeana); I: ASC (Artemisia
scoparia). Conc.: concentration. To investigate ERa
expression, cells were exposed to each extract for 72 h at
two concentrations (10 or 200 mg/mL) to stimulate or
inhibit proliferation. In addition, cyclin D1 and Bcl-2
expression levels were determined in cells exposed to each
extract at a concentration of 200 mg/mL for 72 h.
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Figure 2 Effect of Artemisia extracts on apoptosis induction
in estrogen receptor-a positive human breast MCF-7 cells
A: control; B: AST (Artemisia stolonifera); C: ASE (Artemisia
selengensis); D: AJA (Artemisia japonica); E: AMO (Artemisia
Montana); F: ACA (Artemisia capillaris); G: ASY (Artemisia syl-
vatica); H: AKE (Artemisia keiskeana); I: ASC (Artemisia sco-
paria). Cells were exposed to each extracts at a concentra-
tion of 200 μg/mL for 72 h.
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suggest that cyclin D1 is overexpressed in breast cancer,
29,30 and that it is associated with ER positivity in breast
cancer.31-33 These results suggest that the regulation of
cellular proliferation in MCF-7 cells by Artemisia
extracts was related to ERa signaling.
Moreover, the induction of apoptosis by the Artemisia
extracts is supported by evidence that the rate of
apoptotic cells was increased in MCF-7 cells exposed
to high concentrations of extract. Apoptosis (i.e.,
programmed cell death) is essential for tissue
development and homeostasis. The mechanism of
apoptosis involves a balance between factors that
induce and those that inhibit the process. Recently,
pro-apoptotic agents have been proposed for cancer
chemotherapy.
Much effort has been devoted to the search for new
agents for the therapy, and several traditional
plant-derived products have been found to be
potentially useful. The anticancer activities of
Artemisia spp. (e.g., AST, AKE, and ASC),
demonstrated in the present study, make them
hypothetically useful for further development as a
chemotherapeutical agent targeted at ERa-related
signaling pathway in human breast cancer.
REFERENCES
1 Donald TC, Peterson DM, Walker AA, et al.
Afterload-induced homeometricautoregulation in isolated
cardiac muscle. Am J Physiol 1976; 231(2): 545-550.
2 Ferreira JF, Luthria DL, Sasaki T, et al. Flavonoids from
Artemisia annua L. as antioxidants and their potential
synergism with artemisinin against malaria and cancer.
Molecules 2010; 15(5): 3135-3170.
3 EJ Choi, HS Park, JH Lee, et al. Anticancer, antiobesity,
and anti-inflammatory activity of Artemisia species in
vitro. J Trand Chinese Med 2013; 33(1): 92-97.
4 Hu YQ, Tan RX, Chu MY, et al. Apoptosis in human
hepatoma cell line SMMC-7721 induced by water-soluble
macromolecular components of Artemisia Capillaris
Thunberg. Jpn J Cancer Res 2000; 91(1): 113-117.
5 Vuong TT, Prydz K, Tveit H. Differences in the apical
and basolateral pathways for glycosaminoglycan
biosynthesis in Madin-Darby canine kidney cells.
Glycobiology 2006; 16(4): 326-332.
6 Kim YS, Bahn KN, Hah CK, et al. Inhibition of 7,
12-dimethylbenz[a]anthracene induced mouse skin
carcinogenesis by Artemisia capillaris. J Food Sci 2008; 73
(1): T16-T20.
7 TaghizadehRabe SZ, Mahmoudi M, Ahi A, et al.
Antiproliferative effects of extracts from Iranian Artemisia
species on cancer cell lines. Pharm Biol 2011; 49(9): 962-
969.
8 Sarath VJ, So CS, Won YD, et al. Artemisia
princepsvarorientalis induces apoptosis in human breast
cancer MCF-7 cells. Anticancer Res 2007; 27(6B): 3891-
3898.
9 Kim DH, Na HK, Oh TY, et al. Eupatilin, a
pharmacologically active flavone derived from Artemisia
plants, induces cell cycle arrest in ras-transformed human
mammary epithelial cells. Biochem Pharmacol 2004; 68
(6): 1081-1087.
10 Stavri M, Ford CH, Bucar F, et al. Bioactive constituents
of Artemisia monosperma. Phytochemistry 2005; 66(2):
233-239.
11 Jeong MA, Lee KW, Yoon DY, et al. Jaceosidin, a
pharmacologically active flavone derived from Artemisia
argyi, inhibits phorbol-ester-induced upregulation of
COX-2 and MMP-9 by blocking phosphorylation of
ERK-1 and -2 in cultured human mammary epithelial
cells. Ann N Y AcadSci 2007; 1095: 458-466.
12 Gilbert FJ. Breast cancer screening in high risk women.
Cancer Imaging 2008; 8: S6-S9.
13 Bethesda, MD. SEER Cancer Statistics Review
1975-2010, based on November 2012 SEER data
submission, posted to the SEER web site, Cited 2013-05.
Available from URL: Http://seer.cancer.gov/csr/1975_
2010/.
14 Plaza-Menacho I, Morandi A, Robertson D, et al.
Targeting the receptor tyrosine kinase RET sensitizes
breast cancer cells to tamoxifen treatment and reveals a
role for RET in endocrine resistance. Oncogene 2010; 29
(33): 4648-4657.
15 Cragg GM, Newman DJ. Discovery and development of
antineoplastic agents from natural sources. Cancer Invest
1999; 17(2): 153-163.
16 Cragg GM, Newman DJ. Antineoplastic agents from
natural sources: achievements and future directions. Exp
Opin Invest Drugs 2000; 9(12): 2783-2797.
17 Newman DJ, Cragg GM, Holbeck S, et al. Natural
products and derivatives as leads to cell cycle pathway
targets in cancer chemotherapy. Curr Cancer Drug Targets
2002; 2(4): 279-308.
18 Newman DJ, Cragg GM, Snader KM. Natural products
as sources of new drugs over the period 1981-2002. J Nat
Products 2003; 66(7): 1022-1037.
19 Björnström L, Sjöberg M. Mechanisms of estrogen
receptor signaling: convergence of genomic and
nongenomic actions on target genes. Mol Endocrinol
2005; 19(4): 833-842.
20 Sperelakis N. Properties of calcium channels in cardiac
muscle and vascular smooth muscle. Mol Cell Biochem
1990; 99(2): 97-109.
21 Sirtori CR, Arnoldi A, Johnson SK. Phytoestrogens: end
of a tale? Ann Med 2005; 37(6): 423-438.
22 Oh SM, Kim YP, Chung KH. Biphasic effects of
kaempferol on the estrogenicity in human breast cancer
cells. Arch Pharm Res 2006; 29(5): 354-362.
23 Hsu JT, Hung HC, Chen CJ, et al. Effects of the dietary
phytoestrogen biochaninA on cell growth in the
mammary carcinoma cell line MCF-7. J Nutr Biochem
1999; 10(9): 510-517.
24 Tamir S, Eizenberg M, Somjen D, et al. Estrogenic and
antiproliferative properties of glabridin from licorice in
human breast cancer cells. Cancer Res 2000; 60(20):
5704-5709.
25 Kedar RP, Bourne TH, Powles TJ, et al. Effects of
tamoxifen on uterus and ovaries of postmenopausal
662
Choi EJ et al. / Experimental Study
JTCM |www. journaltcm. com October 15, 2013 |Volume 33 | Issue 5 |
women in a randomised breast cancer prevention trial.
Lancet 1994; 343(8909): 1318-1321.
26 Han J, Ye M, Qiao X, et al. Characterization of phenolic
compounds in the Chinese herbal drug Artemisia Annua
by liquid chromatography coupled to electrospray
ionization mass spectrometry. J Pharm Biomed Anal 2008;
47(3): 516-525.
27 Ma CM, Hattori M, Chen HB, et al. Profiling the
phenolic compounds of Artemisia pectinata by
HPLC-PAD-MSn. Phytochem Anal 2008; 19(4):
294-300.
28 Musgrove EA, Lee CS, Buckley MF, et al. Cyclin D1
induction in breast cancer cells shortens G1 and is
sufficient for cells arrested in G1 to complete the cell
cycle. Proc Natl Acad Sci USA 1994; 91(17): 8022-8026.
29 Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression
and amplification of cyclin genes in human breast cancer.
Oncogene 1993; 8(8): 2127-2133.
30 Bartkova J, Lukas J, Müller H, et al. Cyclin D1 protein
expression and function in human breast cancer. Int J
Cancer 1994; 57(1): 353-361.
31 Barbareschi M, Pelosio P, Caffo O, et al. Cyclin-D1-gene
amplification and expression in breast carcinoma: relation
with clinicopathologic characteristics and with
retinoblastoma gene product, p53 and p21WAF1
immunohistochemical expression. Int J Cancer 1997; 74
(2): 171-174.
32 Utsumi T, Yoshimura N, Maruta M, et al. Correlation of
cyclin D1 MRNA levels with clinico-pathological
parameters and clinical outcome in human breast
carcinomas. Int J Cancer 2000; 89(1): 39-43.
33 Butt AJ, McNeil CM, Musgrove EA, et al. Downstream
targets of growth factor and oestrogensignalling and
endocrine resistance: the potential roles of c-Myc, cyclin
D1 and cyclin E. Endocr Relat Cancer 2005; 12:
S47-S59.
663
